Nachrichten zu Arrowhead Pharmaceuticals

Startseite > Aktien > Arrowhead Pharmaceuticals > Nachrichten

Arrowhead Pharmaceuticals Aktie

Aktie

ISIN: US04280A1007 WKN: A2AGYB SYM: ARWR Land Flagge US

USA

Zur Watchlist hinzufügen Zum Portfolio hinzufügen

Zum Portfolio hinzufügen

18,130

USD

-3,67 %

-0,690 USD

Letzter Kurs 02:00:00 Nasdaq

Geldkurs

07.10.24

18,130

USD

2.400 STK

Briefkurs

07.10.24

18,150

USD

4.300 STK

Arrowhead Pharmaceuticals Aktie kaufen

Kauf

Verkauf

Neueste Nachrichten

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity 23.09.24 · Business Wire (engl.) · Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran 10.09.24 · Business Wire (engl.) · Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals Presents New Pivotal Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome 02.09.24 · Business Wire (engl.) · Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals to Present New Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome 21.08.24 · Business Wire (engl.) · Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals to Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE and ARO-ALK7, Into Clinical Studies 14.08.24 · Business Wire (engl.) · Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals Reports Fiscal 2024 Third Quarter Results 08.08.24 · Business Wire (engl.) · Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals Announces $500 Million Strategic Financing Facility with Sixth Street 08.08.24 · Business Wire (engl.) · Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) 29.07.24 · Business Wire (engl.) · Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Third Quarter Results 24.07.24 · Business Wire (engl.) · Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial 25.06.24 · Business Wire (engl.) · Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals Presents Preclinical Data on New RNAi-Based Obesity Program ARO-INHBE 24.06.24 · Business Wire (engl.) · Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 PALISADE Study in Patients with Familial Chylomicronemia Syndrome 03.06.24 · Business Wire (engl.) · Arrowhead Pharmaceuticals

1
2
3
…
4

Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran 156 Leser
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-INHBE ... 112 Leser

Arrowhead Pharmaceuticals Presents Preclinical Data on New RNAi-Based Obesity Program ARO-INHBE 180 Leser
Arrowhead Pharmaceuticals to Present New Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran ... 168 Leser
Arrowhead Pharmaceuticals Presents New Pivotal Phase 3 Data at ESC 2024 from PALISADE Study of ... 168 Leser
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic ... 160 Leser
Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran 156 Leser
Arrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular ... 148 Leser
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-DM1 ... 144 Leser
Arrowhead Pharmaceuticals Closes Underwritten Offering with Gross Proceeds of $450.0 Million 144 Leser
Arrowhead Presents New Phase 2 Data on Plozasiran and Zodasiran at AHA 2023 140 Leser
Arrowhead Pharmaceuticals Reports Fiscal 2023 Year End Results 136 Leser